Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9935276 | 0.84 | CYP19A1 (0.54) | CYP19A1SIGMAR1CA1CA2PLAU | |
| SCHEMBL1800050 | 0.79 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL7214533 | 0.75 | IDO1 (0.53) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL17956326 | 0.75 | IDO1 (0.53) | IDO1CYP19A1ADRA2ASIGMAR1ANPEP | |
| SCHEMBL835059 | 0.74 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL29593942 | 0.74 | HTR2A (0.52) | IDO1CYP19A1ADRA2APLAU | |
| SCHEMBL29447948 | 0.74 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL714536 | 0.74 | HTR2A (0.52) | IDO1CYP19A1ADRA2APLAU | |
| SCHEMBL22052056 | 0.74 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL2974609 | 0.74 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | claimed |
| EP-3634958-B1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-21 | — | — | EP | claimed |
| US-20200199113-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-25 | — | — | US | claimed |
| EP-3634958-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2020-04-15 | — | — | EP | claimed |
| CN-110997661-A | Cyclopropyl ureaplatin 2 receptor and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2020-04-10 | — | — | CN | claimed |
| WO-2018227067-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-13 | — | — | WO | claimed |
| CN-110997661-B | Cyclopropyl ureaplatin 2 receptor and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3634958-B1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20200199113-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3634958-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-110997661-A | Cyclopropyl ureaplatin 2 receptor and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2020-04-10 | — | — | CN | disclosed |
| CN-106957317-B | Novel pyrazole derivatives | 持田制药株式会社 | 2019-12-31 | — | — | CN | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-01 | — | — | US | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| CN-1231465-C | Biphenylsulfonyl cyanamides, method for the production thereof and use thereof as medicaments | AVENTIS PHARMACEUTIC DEUTSCHLA (DE) | 2005-12-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | IDO1 1503/4885CYP19A1 4315/4885ADRA2A 539/4885 |
| US-20200199113-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | IDO1 1503/4885CYP19A1 4315/4885ADRA2A 539/4885 |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | IDO1 3068/4885CYP19A1 862/4885ADRA2A 234/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | IDO1 3219/4885CYP19A1 557/4885ADRA2A 277/4885 |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | GPR119, GPR27, GPR65 | IDO1 3155/4885CYP19A1 1065/4885ADRA2A 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.